Stockscreener 앱 받기
0.0178
4.71%
0.0008
Galera Therapeutics Inc 주식(GRTX)의 최신 뉴스
North American Morning Briefing : Stock Futures -2- - MarketScreener
Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com
Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Lelezard
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics extends agreement deadline - Investing.com Australia
Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa
Galera Therapeutics Inc. (GRTX) reports earnings - Quartz
Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Galera Therapeutics holds annual stockholder meeting - Investing.com
Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Nasdaq
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Twelve option delistings on December 23rd - TipRanks
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA Today
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
UroGen Appoints Chris Degnan as Chief Financial Officer - Yahoo Finance
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire
Galera Therapeutics faces Nasdaq delisting - Investing.com
"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BioSpectrum Asia
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive
Why Galera Therapeutics (GRTX) Stock Is Nosediving - TradingView
Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics Enacts Plan to Deter Hostile Takeovers - TipRanks
Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire
Oral Mucositis Treatment Market Size & Share Report, 2032 - Global Market Insights
Radiotherapy Induced Oral Mucositis Treatment Market, 2032 - Global Market Insights
Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - Yahoo Finance
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - TradingView
2023 gainers and losers: Positive trial outcomes and M&As propel biopharma stocks to strong finish - BioWorld MedTech
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update - Yahoo Finance
GALERA THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) - marketscreener.com
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News - Nasdaq
FDA Issues CRL for Avasopasem for Severe Mucositis in Head & Neck Cancer - CancerNetwork
FDA Rejects NDA for Avasopasem in RT-Induced Severe Oral Mucositis - Targeted Oncology
10 Approvals To Look Out For In Q3 2023 - insights.citeline.com
Contract Suit Alleges Drug Developer Improperly Analyzed Clinical Trial Data - Law.com
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer - Yahoo Finance
Factor Thisâ„¢ Energy Understood. All Factored In. - FinancialContent
Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation - 24/7 Wall St.
FDA Grants Priority Review to NDA of Avasopasem for RT-Induced Severe Oral Mucositis - Targeted Oncology
Sofinnova Venture Partners IX Cuts Stake in Galera Therapeutics (GRTX) - Nasdaq
0.77%
1.53%
자본화:
|
볼륨(24시간):